This is to invest $714 mn in a new company called Galvani Bioelectronics. The JV will get access to GSK’s drug development and disease biology expertise, whereas Verily will provide miniature electronics, data and software for clinical purposes. Galvani will have about 30 scientists, engineers, and doctors to start with. GSK will work on interfacing devices with human nerves to figure out therapies.

Alphabet Inc’s Verily Life Sciences forming a JV with GlaxoSmithKline

Leave a Reply

Your email address will not be published. Required fields are marked *